Levin Capital Strategies L.P. Increases Holdings in Kenvue Inc. $KVUE

Levin Capital Strategies L.P. grew its position in shares of Kenvue Inc. (NYSE:KVUE) by 245.4% during the 1st quarter, Holdings Channel.com reports. The institutional investor owned 196,036 shares of the company’s stock after acquiring an additional 139,279 shares during the quarter. Levin Capital Strategies L.P.’s holdings in Kenvue were worth $3,380,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also recently modified their holdings of KVUE. Vanguard Group Inc. grew its holdings in shares of Kenvue by 0.7% in the fourth quarter. Vanguard Group Inc. now owns 234,951,484 shares of the company’s stock worth $4,052,913,000 after acquiring an additional 1,604,040 shares during the period. State Street Corp lifted its holdings in Kenvue by 3.5% in the fourth quarter. State Street Corp now owns 118,865,134 shares of the company’s stock valued at $2,050,424,000 after acquiring an additional 4,063,257 shares during the period. Geode Capital Management LLC lifted its holdings in Kenvue by 0.8% in the fourth quarter. Geode Capital Management LLC now owns 49,862,574 shares of the company’s stock valued at $856,778,000 after acquiring an additional 371,322 shares during the period. Independent Franchise Partners LLP boosted its position in Kenvue by 56.3% in the fourth quarter. Independent Franchise Partners LLP now owns 48,146,476 shares of the company’s stock worth $830,527,000 after purchasing an additional 17,343,785 shares during the last quarter. Finally, Norges Bank purchased a new position in Kenvue in the fourth quarter worth about $756,862,000. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, General Counsel Matthew Orlando sold 38,491 shares of the business’s stock in a transaction that occurred on Friday, May 8th. The stock was sold at an average price of $17.66, for a total value of $679,751.06. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Corporate insiders own 1.59% of the company’s stock.

Kenvue Stock Performance

NYSE:KVUE opened at $19.12 on Thursday. The stock has a 50-day simple moving average of $18.30 and a two-hundred day simple moving average of $17.90. Kenvue Inc. has a 52-week low of $14.02 and a 52-week high of $22.87. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.70 and a current ratio of 0.98. The firm has a market capitalization of $36.71 billion, a PE ratio of 22.49, a P/E/G ratio of 1.44 and a beta of 0.47.

Kenvue (NYSE:KVUE) last issued its quarterly earnings results on Thursday, May 7th. The company reported $0.32 EPS for the quarter, topping analysts’ consensus estimates of $0.27 by $0.05. Kenvue had a return on equity of 20.81% and a net margin of 10.61%.The business had revenue of $3.91 billion during the quarter, compared to analysts’ expectations of $3.84 billion. During the same quarter in the prior year, the business posted $0.24 earnings per share. The business’s quarterly revenue was up 4.5% on a year-over-year basis. Analysts forecast that Kenvue Inc. will post 1.16 EPS for the current year.

Kenvue Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Wednesday, May 27th. Investors of record on Wednesday, May 13th were paid a dividend of $0.2075 per share. This represents a $0.83 annualized dividend and a yield of 4.3%. The ex-dividend date of this dividend was Wednesday, May 13th. Kenvue’s dividend payout ratio (DPR) is 97.65%.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the company. Barclays boosted their price target on Kenvue from $18.00 to $19.00 and gave the company an “equal weight” rating in a research note on Tuesday. Wall Street Zen raised shares of Kenvue to a “buy” rating in a report on Sunday, July 12th. Zacks Research lowered shares of Kenvue from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 7th. Weiss Ratings upgraded shares of Kenvue from a “hold (c-)” rating to a “hold (c)” rating in a research report on Monday, June 15th. Finally, Citigroup reduced their target price on shares of Kenvue from $20.00 to $19.00 and set a “neutral” rating for the company in a report on Wednesday, April 15th. Three research analysts have rated the stock with a Buy rating and thirteen have assigned a Hold rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $19.58.

Kenvue Company Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.